
|Videos|October 10, 2016
How Can Access to PCSK9 Inhibitors be Improved?
Author(s)Lauren Santye, Assistant Editor
Mark Tesell, PharmD, BCPS, clinical consultant pharmacist for UMass Medical School Clinical Pharmacy Services, discusses potential solutions for access to cholesterol lowering drugs to improve.
Advertisement
Mark Tesell, PharmD, BCPS, clinical consultant pharmacist for UMass Medical School Clinical Pharmacy Services, discusses potential solutions for access to cholesterol lowering drugs to improve.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists at the Forefront: Initiating, Monitoring, and Identifying Candidates for VMAT2 Therapy
2
Up to 5 Cups of Coffee Daily Safe—and Benficial—for Most Adults
3
Pharmacist Outreach Doubles SGLT2 Inhibitor Uptake in CKD
4
mRNA COVID-19 Booster Outperforms Protein-Based Shot on Antibodies, But Both Cut Infections Over 12 Months
5





































































































